Scientists Found Novel Way To "Switch on" Tumour Suppressors That Have Been Silenced

A team of scientists from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) and their collaborators from the Harvard Stem Cell Institute have found that a novel noncoding ribonucleic acid (RNA) offers the potential for “switching on” of tumour suppressors that have been shut off.

The research group, led by Professor Daniel Tenen, Director of CSI Singapore, demonstrated for first time that RNA interacts with an enzyme essential for DNA methylation, known as DNA methyl transferase 1 (DNMT1), offering strategies for the treatment of diseases such as cancer.

In this study, the researchers focused on a new class of RNAs, which is critical in regulating DNA methylation. This is a process in which certain building blocks of DNA, the genetic code, are chemically modified without resulting in a change in the code itself. DNA methylation is associated with silencing of gene expression and found in many diseases. For example, in cancer, genes called tumour suppressors, which inhibit tumour formation, are often silenced or shut off in the cancer cells, and this is associated with DNA methylation.

This novel study was first published online in the research journal Nature on 9 October 2013.

How the novel noncoding RNA inhibits DNA methylation

The study focused on this novel noncoding RNA in a specific tumour suppressor, known as CEBPA. The silencing of CEPBA is associated with Acute Myeloid Leukemia, lung cancer and other types of cancer. The scientists demonstrated that the noncoding RNA binds to the enzyme DNMT1 and prevents DNA methylation of the CEBPA gene. This principle, which is likely to extend to thousands of other genes, can potentially be used to “switch on” tumour suppressors that have been shut off.

Prof Tenen said, “We started out by studying the noncoding RNA to satisfy our scientific curiosity. In the process, we discovered the novel finding that RNA inhibits methylation and experimentally, we can introduce RNAs to ‘switch on’ tumour suppressors which have been shut off. Our results suggest strategies for gene-selective demethylation of therapeutic targets in human diseases such as cancer.”

Further Research

In the next phase of their research, the scientists will look into developing tools for targeted activation of other tumour suppressors, besides CEBPA, and investigate the role of RNA in regulating other epigenetic marks.

Media Contact

Kimberley Wang Newswise

More Information:

http://www.nus.edu.sg

All latest news from the category: Life Sciences and Chemistry

Articles and reports from the Life Sciences and chemistry area deal with applied and basic research into modern biology, chemistry and human medicine.

Valuable information can be found on a range of life sciences fields including bacteriology, biochemistry, bionics, bioinformatics, biophysics, biotechnology, genetics, geobotany, human biology, marine biology, microbiology, molecular biology, cellular biology, zoology, bioinorganic chemistry, microchemistry and environmental chemistry.

Back to home

Comments (0)

Write a comment

Newest articles

Under arrest: Using nanofibers to stop brain tumor cells from spreading

Researchers from Japan develop a platform based on nanofibers to trap brain cancer cells as a therapeutic strategy. Our body heals its injuries by essentially replacing damaged cells with new…

New photonic chip for isolating light may be key to miniaturizing quantum devices

Light offers an irreplaceable way to interact with our universe. It can travel across galactic distances and collide with our atmosphere, creating a shower of particles that tell a story…

A traffic light for light-on-a-chip

Integrated photonics allow us to build compact, portable, low-power chip-scale optical systems used in commercial products, revolutionizing today’s optical datacenters and communications. But integrating on-chip optical gain elements to build…

Partners & Sponsors